Page 204 - Read Online

Pan et al. Hepatoma Res 2024;10:3 https://dx.doi.org/10.20517/2394-5079.2023.44 Page 13 of 13

66. Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with
FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017;7:252-63. DOI PubMed PMC
67. Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies
correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov 2021;11:326-39. DOI PubMed
68. Lau DK, Jenkins L, Weickhardt A. Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy. Cancer
Drug Resist 2019;2:568-79. DOI PubMed PMC
69. Lavacchi D, Pellegrini E, Palmieri VE, et al. Immune checkpoint inhibitors in the treatment of renal cancer: current state and future
perspective. Int J Mol Sci 2020;21:4691. DOI PubMed PMC
70. Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with
unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer 2020;8:e000367. DOI PubMed
PMC
71. Mohan A, Griffith KA, Wuchu F, et al. Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: preclinical
evaluation and phase Ib multicenter clinical trial (BilT-04). Clin Cancer Res 2023;29:2394-400. DOI PubMed PMC
72. Zeng TM, Yang G, Lou C, et al. Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for
patients with advanced biliary tract cancer. Nat Commun 2023;14:1340. DOI PubMed PMC
73. Lee HS, Han DH, Cho K, et al. Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables
tumor subtyping. Nat Commun 2023;14:237. DOI PubMed PMC
74. Bao X, Li Q, Chen J, et al. Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-
assisted multiomics analysis. Cancer Immunol Res 2022;10:811-28. DOI PubMed
75. Dong L, Lu D, Chen R, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic
cholangiocarcinoma. Cancer Cell 2022;40:70-87.e15. DOI